Biodesix (BDSX)
(Delayed Data from NSDQ)
$0.42 USD
+0.04 (10.10%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.46 +0.04 (8.75%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDSX 0.42 +0.04(10.10%)
Will BDSX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BDSX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDSX
Avantor, Inc. (AVTR) Q2 Earnings Lag Estimates
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
BDSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sonida Senior Living (SNDA) Reports Q1 Loss, Tops Revenue Estimates
DocGo Inc. (DCGO) Reports Q1 Loss, Misses Revenue Estimates
GeneDx Holdings Corp. (WGS) Q1 Earnings and Revenues Surpass Estimates
Other News for BDSX
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference | BDSX Stock News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 | BDSX Stock News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Biodesix (BDSX) Partners with APAPP to Enhance Lung Cancer Care | BDSX Stock News